Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
  • Patent number: 11672784
    Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: June 13, 2023
    Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, SINGAPORE HEALTH SERVICES PTE LTD
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Yin Chiang Freddy Boey, Jodhbir Singh Mehta, Tina Tzee Ling Howden, Xu Wen Ng, Anthony Herr Cheun Ng
  • Patent number: 11504350
    Abstract: Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 22, 2022
    Assignee: DAY THREE LABS MANUFACTURING INC.
    Inventors: William Z. Levine, Shimon Lecht, Olga Gabay
  • Patent number: 11485700
    Abstract: The present invention relates to a method of producing a compound of formula (I) or a salt of a compound of formula (I). The invention also relates to a compound of formula (I) or a salt of a compound of formula (I) for use in a therapeutic method to achieve one or more therapeutic effects as well as for use in the treatment and/or prevention of certain diseases. Furthermore, the invention provides a pharmaceutical composition comprising one or more compound(s) of formula (I) or salt(s) of compound(s) of formula (I).
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 1, 2022
    Assignee: SYMRISE AG
    Inventors: Bernd Fiebich, Matthias Winkler, Marcus Rudolf Götz, Oskar Koch
  • Patent number: 11439621
    Abstract: Combinations and methods for treating a subject experiencing or at risk of experiencing an undesired consequence of stimulant use are provided. The combinations include topiramate and phentermine. The methods include administering an effective dose of a combination of topiramate and phentermine to a subject. In some embodiments, the methods include administering an effective dose of a combination of topiramate and phentermine to a subject with cocaine use disorder.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: September 13, 2022
    Assignee: University of Kentucky Research Foundation
    Inventor: Craig R. Rush
  • Patent number: 11382799
    Abstract: A tampon and therapeutic delivery device is disclosed and includes a generally cylindrical applicator tube defining a cartridge within which a tampon is slidably received for ejection through one end of the cartridge. A generally hollow cylindrical plunger member is slidably received within an opposite end of the cartridge for ejecting the tampon therefrom. A cannabinoid-infused disintegrable carrier material is partially embedded in and movably held by the tampon for intravaginal delivery when ejected from the cartridge, whereupon the cannabinoid agent is released into the vagina and absorbed through the vaginal mucosa to provide relief of dysmenorrhea. The cartridge has a plurality of slots to permit pre-lubrication of the tampon, if desired, prior to insertion into the vaginal cavity. The system delivers a higher concentration to the muscle of the uterus, the primary site for the dyskinetic muscle contraction, which is the pathophysiologic cause of dysmenorrhea.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: July 12, 2022
    Assignee: BLUEGRASS FARMACEUTICALS, LLC
    Inventor: David M. Tumey
  • Patent number: 11234957
    Abstract: The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and ?-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 1, 2022
    Assignee: SciPharm S.à.r.l
    Inventor: Andreas Kubin
  • Patent number: 11052125
    Abstract: The present invention discloses a composition comprising extracts of Cyperus rotundus, standardized to contain 3-5% w/w total stilbenes, extracts of Garcinia sp., standardized to contain 20% w/w garcinol and extracts of Coleus forskohlii standardized to contain not less than 10% w/w forskolin for the therapeutic management of diet induced obesity and weight gain and related conditions like liver dysfunction, NASH, NAFLD, liver cirrhosis, hypercholesterolemia, hyperlipidemia, kidney dysfunction by bringing about a reduction in body weight, increasing lean body mass and by normalizing the levels of liver enzymes, kidney markers and circulating lipids.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 6, 2021
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Sarang Bani, Anjali Pandey
  • Patent number: 11039636
    Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and/or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Summit Innovation Labs, LLC
    Inventors: Ghebre Egziabher Tzeghai, Haile Mehansho, Satyanarayana Majeti
  • Patent number: 11000505
    Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation. For example, salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: May 11, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Renyu Liu
  • Patent number: 10792276
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 6, 2020
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 10464963
    Abstract: In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 5, 2019
    Assignee: Stephen F. Austin State University
    Inventors: Shiyou Li, Ping Wang, Guangrui Deng, Wei Yuan, Zushang Su
  • Patent number: 10301265
    Abstract: The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of Clostridium botulinum serotype A neurotoxins. The invention also provides methods of using these small-molecule inhibitors to inhibit infections by Clostridium botulinum, as well as, methods of preventing infections by Clostridium botulinum through materials that may be ingested.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: May 28, 2019
    Inventors: Virginia I. Roxas-Duncan, Leonard A. Smith, Nizamettin Gul, John H. Cardellina, II, Rebecca C. Vieira, Susan M. Ensel, David C. H. Yang, Istvan J. Enyedy, Sivanesan Dakshanamurthy, Salimuddin Shah
  • Patent number: 10251902
    Abstract: The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: April 9, 2019
    Assignee: DAE HWA PHARMA CO., LTD.
    Inventors: Jong Hoon Ryu, Jae Hoon Cheong, Chan Young Shin, Dae Sik Jang, Hyung Eun Lee, Hyun Ji Kim, Byeol Ryu, In Ho Jung, Yeong Woo Jo
  • Patent number: 10195176
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 5, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Patent number: 9962366
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 8, 2018
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 9918962
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 20, 2018
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Patent number: 9901596
    Abstract: A method of using dibenzo-alpha-pyrones (DBPs) is provided wherein a subject is administered one or more of the aforementioned resulting in decreased body weight gain. In an embodiment, a 3-OH-DBP, 3,8-(OH)2-DBP, or a combination thereof is administered to an individual to control body weight gain.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 27, 2018
    Assignee: Natreon, Inc.
    Inventor: Chandan K. Sen
  • Patent number: 9809615
    Abstract: Compositions and methods related to anti-cancer terpenoid compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of treating cancer.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: November 7, 2017
    Assignee: STEPHEN F. AUSTIN STATE UNIVERSITY
    Inventors: Shiyou Li, Ping Wang, Guangrui Deng, Wei Yuan, Zushang Su
  • Patent number: 9802962
    Abstract: Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble A? species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular A? aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: October 31, 2017
    Assignees: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, AFASCI, INC.
    Inventors: Duy H Hua, Lee-way Jin, Izumi Maezawa, Xinmin Xie
  • Patent number: 9707219
    Abstract: The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dennis Sprecher, Robert Nicholas Willette
  • Patent number: 9693992
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 4, 2017
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • Patent number: 9526720
    Abstract: The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: December 27, 2016
    Assignee: The Broad Institute, Inc.
    Inventors: Marek Maria Nagiec, Jose R. Perez, Michelle Palmer, Adam Skepner, Eamon Comer
  • Patent number: 9468623
    Abstract: The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: October 18, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hong-xi Xu, Yuan-zhi Lao, Zhi-jie Ding, Hong Zhang, Kai-xian Chen, Hong-sheng Tan, Zhao-xiang Bian, Cheng-yuan Lin, Shi-lin Chen, Da-jian Yang, Ai-ping Lu, Albert Sun Chi Chan
  • Patent number: 9440987
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: September 13, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Asato Kina
  • Patent number: 9428494
    Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 30, 2016
    Assignee: University of Iowa Research Foundation
    Inventor: Thomas Prisinzano
  • Patent number: 9145422
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: September 29, 2015
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Publication number: 20150148409
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 28, 2015
    Inventors: Guangdi WANG, Matthew E. BUROW, Stephen M. BOUE, Thomas E. WIESE, Quan JIANG
  • Publication number: 20150126573
    Abstract: The present invention relates to methods and compositions for the prevention or treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 7, 2015
    Inventors: Jorge Bernardo Boczkowski, Serge Adnot, Maylis Dagouassat, Jean-Marie Gagliolo
  • Publication number: 20150119406
    Abstract: Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble A? species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular A? aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 30, 2015
    Inventors: Duy H. Hua, Lee-way Jin, Izumi Maezawa, Xinmin Xie
  • Publication number: 20150110735
    Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 23, 2015
    Inventor: Steven Hoffman
  • Patent number: 9011905
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 9011906
    Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20150099801
    Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 9, 2015
    Inventors: Wesley Day, Barbara Troupin
  • Publication number: 20150093458
    Abstract: A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6. Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.
    Type: Application
    Filed: September 27, 2014
    Publication date: April 2, 2015
    Inventor: Justin SHER
  • Publication number: 20150087620
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • Publication number: 20150072953
    Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like.
    Type: Application
    Filed: June 16, 2014
    Publication date: March 12, 2015
    Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Bo-Su Lee, Young-Chul Lee, Breanna Moore, Jeong-Bum Nam, Mi-Sun Oh, Mi-Hye Park, Mesfin Yimam, Qian Zhang
  • Publication number: 20150072012
    Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Patent number: 8969371
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: March 3, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 8969406
    Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: March 3, 2015
    Assignee: China Medical University
    Inventors: Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang, Da-Wei Chuang, Juan-Cheng Yang
  • Publication number: 20150057343
    Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Applicant: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire SAURAT
  • Publication number: 20150056166
    Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
  • Patent number: 8957108
    Abstract: The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogs, and in particular, the flavone acetic acid analog, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: February 17, 2015
    Assignee: University of Maryland, Baltimore
    Inventors: Stefanie N. Vogel, Zachary J. Roberts, Jorge Blanco
  • Patent number: 8957057
    Abstract: The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: February 17, 2015
    Assignee: Food Industry Research and Development Institute
    Inventors: Ta-Wei D. Liu, Yen-Lin Chen, Ming-Der Wu, Ming-Jen Cheng, Hui-Ping Chen, Wen-Jung Wu, Kai-Ping Chen, Yu-Shan Lin, Gwo-Fang Yuan
  • Publication number: 20150044295
    Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.
    Type: Application
    Filed: March 20, 2013
    Publication date: February 12, 2015
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Chunseng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
  • Patent number: 8951561
    Abstract: The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 10, 2015
    Assignees: Duke University, Immunolight
    Inventors: Tuan Vo-Dinh, Frederic A. Bourke, Jr.
  • Publication number: 20150038568
    Abstract: A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 5, 2015
    Inventor: Liping Yang
  • Publication number: 20150038569
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Xiaoyu WANG, Kaixian CHEN, Dajian YANG, Shilin CHEN, Chengyuan LIN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150030551
    Abstract: Provided are benzopyran compounds of formula I, for example, pomiferin-3?,4?-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 29, 2015
    Inventor: Seth J. ORLOW
  • Publication number: 20150024055
    Abstract: The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Padmanabh P. BHATT, Hua WANG